Prostate cancer: DNA-based risk assessment

被引：0
|
作者：
Isaacs, William [1 ]
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 16期
关键词：
D O I：
10.1158/1538-7445.PRCA2017-IA02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA02
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [41] DNA-based biosensors
    Zhang, Hongquan
    Liu, Juewen
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2023, 166
  • [42] DNA-Based Machines
    Wang, Fuan
    Willner, Bilha
    Willner, Itamar
    MOLECULAR MACHINES AND MOTORS: RECENT ADVANCES AND PERSPECTIVES, 2014, 354 : 279 - 338
  • [43] A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.
    Shore, Neal D.
    Heath, Elisabeth I.
    Nordquist, Luke T.
    Cheng, Heather H.
    Bhatt, Kamalnayan
    McMullan, Trevor
    Kraynyak, Kimberly
    Lee, Jessica
    Sacchetta, Brian
    Tagawa, Scott T.
    Parikh, Rahul Atul
    Tutrone, Ronald F.
    Garcia, Jorge A.
    Whang, Young E.
    Lin, Jianqing
    Kelly, William Kevin
    Csiki, Ildiko
    Bagarazzi, Mark L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] DNA-based nanodevices
    Liedl, Tim
    Sobey, Thomas L.
    Simmel, Friedrich C.
    NANO TODAY, 2007, 2 (02) : 36 - 41
  • [45] A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.
    Shore, Neal D.
    Heath, Elisabeth I.
    Nordquist, Luke T.
    Cheng, Heather H.
    Bhatt, Kamalnayan
    Carroll, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [46] Risk subtyping and prognostic assessment of prostate cancer based on consensus genes
    Jialin Meng
    Yu Guan
    Bijun Wang
    Lei Chen
    Junyi Chen
    Meng Zhang
    Chaozhao Liang
    Communications Biology, 5
  • [47] Risk subtyping and prognostic assessment of prostate cancer based on consensus genes
    Meng, Jialin
    Guan, Yu
    Wang, Bijun
    Chen, Lei
    Chen, Junyi
    Zhang, Meng
    Liang, Chaozhao
    COMMUNICATIONS BIOLOGY, 2022, 5 (01)
  • [48] DNA testing for high risk of prostate cancer
    Dominika Wokołorczyk
    Hereditary Cancer in Clinical Practice, 10 (Suppl 1)
  • [49] DNA damage phenotype and prostate cancer risk
    Kosti, O.
    Goldman, L.
    Saha, D. T.
    Orden, R. A.
    Pollock, A. J.
    Madej, H. L.
    Hsing, A. W.
    Chu, L. W.
    Lynch, J. H.
    Goldman, R.
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2011, 719 (1-2) : 41 - 46
  • [50] Patient-oriented DNA-based drug for bladder cancer
    Hochberg, Abraham
    Sidi, Abraham A.
    Shalva, Biniamin
    Leibovitch, Ilan
    Shalev, Moshe
    Ohana, Patricia
    HUMAN GENE THERAPY, 2007, 18 (10) : 951 - 951
12345